Figure 2.
Characterization of HSPCs in the BM of single and double mutant mice. Percentages of HSPCs from mouse BM analyzed by flow cytometry 20 weeks after BMT (WT, n = 5; Srsf2P95H/+, n = 5; Runx1 knockout, n = 5; double mutant, n = 6). (A) Lin− cells. (B) Lin−Sca-1+c-Kit+ (LSK) cells. (C) Long-term HSCs (LT-HSCs; LSK CD150+CD48−) and multipotent progenitor 1 cells (MPP1; LSK CD150−CD48−). (D) MPP2 (LSK CD150+CD48+) and MPP3/4 (LSK CD150−CD48+). (E) CMPs (Lin−Sca-1−c-Kit+CD16/CD32−CD34+), GMPs (Lin−Sca-1−c-Kit+CD16/CD32+CD34+), and megakaryocyte-erythrocyte progenitors (MEPs; Lin−Sca-1−c-Kit+CD16/CD32−CD34−). Data are mean ± SEM. Significance was determined by 1-way ANOVA with Tukey post hoc test. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. KO, knockout.

Characterization of HSPCs in the BM of single and double mutant mice. Percentages of HSPCs from mouse BM analyzed by flow cytometry 20 weeks after BMT (WT, n = 5; Srsf2P95H/+, n = 5; Runx1 knockout, n = 5; double mutant, n = 6). (A) Lin− cells. (B) Lin−Sca-1+c-Kit+ (LSK) cells. (C) Long-term HSCs (LT-HSCs; LSK CD150+CD48−) and multipotent progenitor 1 cells (MPP1; LSK CD150−CD48−). (D) MPP2 (LSK CD150+CD48+) and MPP3/4 (LSK CD150−CD48+). (E) CMPs (Lin−Sca-1−c-Kit+CD16/CD32−CD34+), GMPs (Lin−Sca-1−c-Kit+CD16/CD32+CD34+), and megakaryocyte-erythrocyte progenitors (MEPs; Lin−Sca-1−c-Kit+CD16/CD32−CD34−). Data are mean ± SEM. Significance was determined by 1-way ANOVA with Tukey post hoc test. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. KO, knockout.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal